Huantao Zong1, Chenchen Yang, Xiaoxia Peng, Yong Zhang. 1. Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, No. 8 Gong Ti Nan Road (or Beijing Worker Stadium South Road), Chao Yang District, Beijing 100020, China.
Abstract
PURPOSE: The purpose of this analysis was to evaluate the efficacy and safety of desmopressin for the treatment of nocturia. METHODS: Databases including MEDLINE, EMBASE, ISI web of knowledge, the Cochrane Controlled Trial Register of Controlled Trials and Chinese Biological Medical Database were searched to identify randomized controlled trials (RCTs) that referred to the efficacy and safety of desmopressin for the treatment of nocturia. A systematic review and meta-analysis were conducted. RESULTS: Five studies involving 619 participants were included for the meta-analysis, and 8 RCTs of cross-over design were also identified for the systematic review. The analysis revealed that desmopressin might significantly decrease the frequency of nocturnal voids, nocturnal urine volume and nocturnal diuresis, potentially resulting in an extended duration of the first sleep period and improved sleep quality. The adverse effects of desmopressin were similar to those observed in the placebo group. CONCLUSIONS: Administered desmopressin was an effective and well-tolerated treatment for nocturia.
PURPOSE: The purpose of this analysis was to evaluate the efficacy and safety of desmopressin for the treatment of nocturia. METHODS: Databases including MEDLINE, EMBASE, ISI web of knowledge, the Cochrane Controlled Trial Register of Controlled Trials and Chinese Biological Medical Database were searched to identify randomized controlled trials (RCTs) that referred to the efficacy and safety of desmopressin for the treatment of nocturia. A systematic review and meta-analysis were conducted. RESULTS: Five studies involving 619 participants were included for the meta-analysis, and 8 RCTs of cross-over design were also identified for the systematic review. The analysis revealed that desmopressin might significantly decrease the frequency of nocturnal voids, nocturnal urine volume and nocturnal diuresis, potentially resulting in an extended duration of the first sleep period and improved sleep quality. The adverse effects of desmopressin were similar to those observed in the placebo group. CONCLUSIONS: Administered desmopressin was an effective and well-tolerated treatment for nocturia.
Authors: Philip van Kerrebroeck; Paul Abrams; David Chaikin; Jenny Donovan; David Fonda; Simon Jackson; Poul Jennum; Theodore Johnson; Gunnar Lose; Anders Mattiasson; Gary Robertson; Jeff Weiss Journal: Neurourol Urodyn Date: 2002 Impact factor: 2.696
Authors: Philip van Kerrebroeck; Masoumeh Rezapour; Ariane Cortesse; Joachim Thüroff; Anders Riis; Jens Peter Nørgaard Journal: Eur Urol Date: 2007-01-16 Impact factor: 20.096
Authors: Donald L Bliwise; Daniel J Foley; Michael V Vitiello; Farzaneh Pour Ansari; Sonia Ancoli-Israel; James K Walsh Journal: Sleep Med Date: 2008-08-13 Impact factor: 3.492